PROTEIN CROSS-LINKING INHIBITOR
    1.
    发明申请
    PROTEIN CROSS-LINKING INHIBITOR 有权
    蛋白交联抑制剂

    公开(公告)号:US20110212919A1

    公开(公告)日:2011-09-01

    申请号:US13058647

    申请日:2009-08-11

    CPC分类号: C07F5/025 A61K31/69

    摘要: The present invention provides a protein cross-linking inhibitor containing a compound represented by any of the following formulas (1)-(13), or a pharmaceutically acceptable salt thereof: R3—[—X—B(ZR1)—Y—B(ZR2)—W—]n—R4,  (1) R3—[—X—B(ZR1)—Y—]n—R4,  (2) R3—[—B(ZR1)—Y—B(ZR2)—W—]n—R4,  (3) R3—[—X—B(ZR1)—]n—R4,  (4) R3—[—B(ZR2)—W—]n—R4,  (5) R3—X—B(ZR1)-T[B(ZR2)—W—R4]2,  (6) R3—B(OH)2,  (7) R3—B(ZR1)—X—B(ZR2)—R4,  (8) R3—B(R1)—O—B(R2)—R4,  (9) R3—[—X—B(ZR1)—Y—B(ZR2)—]n—R4,  (10) R3—[—X—B(ZR1)—Y—B(ZR2)—W-Q-]n—R4,  (11) R3—[—P—X—B(ZR1)—Y—B(ZR2)—W—]n—R4,  (12) [R3—X—B(ZR1)—Y]2B(ZR2),  (13) wherein each symbol is as defined in the DESCRIPTION.

    摘要翻译: 本发明提供一种蛋白质交联抑制剂,其含有下述式(1) - (13)中任一项所示的化合物或其药学上可接受的盐:R3 - [ - X-B(ZR1)-Y-B ZR2)-W-] n-R4,(1)R3 - [ - X-B(ZR1)-Y-] n-R4,(2)R3 - [ - B(ZR1)-Y-B(ZR2) - W - ] n-R4,(3)R3 - [ - X-B(ZR1) - ] n-R4,(4)R3 - [ - B(ZR2)-W-] n-R4,(5) X-B(ZR1)-T [B(ZR2)-W-R4] 2,(6)R3-B(OH)2,(7)R3-B(ZR1)-X-B(ZR2)-R4, (8)R3-B(R1)-O-B(R2)-R4,(9)R3 - [ - X-B(ZR1)-Y-B(ZR2) - ] n-R4,(10) [-X-B(ZR1)-Y-B(ZR2)-WQ-] n-R4,(11)R3 - [ - P-X-B(ZR1)-Y-B(ZR2)-W-] n -R4,(12)[R3-X-B(ZR1)-Y] 2B(ZR2),(13)其中每个符号如说明书中所定义。

    Protein cross-linking inhibitor
    2.
    发明授权
    Protein cross-linking inhibitor 有权
    蛋白质交联抑制剂

    公开(公告)号:US08853424B2

    公开(公告)日:2014-10-07

    申请号:US13058647

    申请日:2009-08-11

    CPC分类号: C07F5/025 A61K31/69

    摘要: The present invention provides a protein cross-linking inhibitor containing a compound represented by any of the following formulas (1)-(13), or a pharmaceutically acceptable salt thereof: R3—[—X—B(ZR1)—Y—B(ZR2)—W—]n—R4,  (1) R3—[—X—B(ZR1)—Y—]n—R4,  (2) R3—[—B(ZR1)—Y—B(ZR2)—W—]n—R4,  (3) R3—[—X—B(ZR1)—]n—R4,  (4) R3—[—B(ZR2)—W—]n—R4,  (5) R3—X—B(ZR1)-T[B(ZR2)—W—R4]2,  (6) R3—B(OH)2,  (7) R3—B(ZR1)—X—B(ZR2)—R4,  (8) R3—B(R1)—O—B(R2)—R4,  (9) R3—[—X—B(ZR1)—Y—B(ZR2)—]n—R4,  (10) R3—[—X—B(ZR1)—Y—B(ZR2)—W-Q-]n—R4,  (11) R3—[—P—X—B(ZR1)—Y—B(ZR2)—W—]n—R4,  (12) [R3—X—B(ZR1)—Y]2B(ZR2),  (13) wherein each symbol is as defined in the DESCRIPTION.

    摘要翻译: 本发明提供一种蛋白质交联抑制剂,其含有下述式(1) - (13)中任一项所示的化合物或其药学上可接受的盐:R3 - [ - X-B(ZR1)-Y-B ZR2)-W-] n-R4,(1)R3 - [ - X-B(ZR1)-Y-] n-R4,(2)R3 - [ - B(ZR1)-Y-B(ZR2) - W - ] n-R4,(3)R3 - [ - X-B(ZR1) - ] n-R4,(4)R3 - [ - B(ZR2)-W-] n-R4,(5) X-B(ZR1)-T [B(ZR2)-W-R4] 2,(6)R3-B(OH)2,(7)R3-B(ZR1)-X-B(ZR2)-R4, (8)R3-B(R1)-O-B(R2)-R4,(9)R3 - [ - X-B(ZR1)-Y-B(ZR2) - ] n-R4,(10) [-X-B(ZR1)-Y-B(ZR2)-WQ-] n-R4,(11)R3 - [ - P-X-B(ZR1)-Y-B(ZR2)-W-] n -R4,(12)[R3-X-B(ZR1)-Y] 2B(ZR2),(13)其中每个符号如说明书中所定义。

    Bisboron compound
    5.
    发明授权
    Bisboron compound 有权
    Bisboron化合物

    公开(公告)号:US08017809B2

    公开(公告)日:2011-09-13

    申请号:US12094968

    申请日:2006-11-24

    IPC分类号: C07F5/02 A61K31/69

    CPC分类号: C07F5/025

    摘要: A bisboron compound represented by the general formula (I): wherein B represents a boron atom, Y represents an oxygen or sulfur atom, R1 and R2 independently represent a monocyclic aromatic group, a polycyclic aromatic group, or a heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur atoms, R3 represents a hydrogen atom; —(CH2)m—NR4R5; —CO—(CH2)m—NR4R5; —COCH(NH2)R6; —CHR7R8; —CH2CH(NH2)—R9; quinolyl substituted with C1-C4 alkyl group; or C1-C4 alkyl substituted with pyridyl, piperidino or pyrrolidinyl group, and X represents a monocyclic aromatic group, a polycyclic aromatic group or a heterocyclic group, which may be the same as or different from R1 and R2, or a bifunctional group having a monocyclic aromatic group, polycyclic aromatic group or heterocyclic group bonded to each side of a group selected from the group consisting of a single bond, O, CH2, S, SO2, CH2OCH2, OCH2, OCH2CH2OCH2, OCH2OCH2CH2 and CH2OCH2CH2, or a salt thereof, and a composition for controlling the intracellular calcium concentration, which comprises the compound or salt thereof as an active ingredient.

    摘要翻译: 由通式(I)表示的双硼化合物:其中B表示硼原子,Y表示氧或硫原子,R1和R2独立地表示单环芳基,多环芳基或含有至少一个 选自氧,氮和硫原子的杂原子,R 3表示氢原子; - (CH 2)m -NR 4 R 5; -CO-(CH 2)m -NR 4 R 5; -COCH(NH 2)R 6; -CHR7R8; -CH 2 CH(NH 2)-R 9; 被C1-C4烷基取代的喹啉基; 或被吡啶基,哌啶子基或吡咯烷基取代的C1-C4烷基,X表示可以与R1和R2相同或不同的单环芳基,多环芳基或杂环基,或具有 或选自由单键,O,CH2,S,SO2,CH2OCH2,OCH2,OCH2CH2OCH2,OCH2OCH2CH2和CH2OCH2CH2组成的组中的一个基团键合的单环芳基,多环芳基或杂环基,或其盐, 以及用于控制细胞内钙浓度的组合物,其包含其化合物或其盐作为活性成分。

    NOVEL BISBORON COMPOUND
    6.
    发明申请
    NOVEL BISBORON COMPOUND 有权
    新颖的BISBONON化合物

    公开(公告)号:US20100087645A1

    公开(公告)日:2010-04-08

    申请号:US12094968

    申请日:2006-11-24

    IPC分类号: C07F5/02

    CPC分类号: C07F5/025

    摘要: A bisboron compound represented by the general formula (I): wherein B represents a boron atom, Y represents an oxygen or sulfur atom, R1 and R2 independently represent a monocyclic aromatic group, a polycyclic aromatic group, or a heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur atoms, R3 represents a hydrogen atom; —(CH2)m—NR4R5; —CO—(CH2)m—NR4R5; —COCH(NH2)R6; —CHR7R8; —CH2CH(NH2)—R9; quinolyl substituted with C1-C4 alkyl group; or C1-C4 alkyl substituted with pyridyl, piperidino or pyrrolidinyl group, and X represents a monocyclic aromatic group, a polycyclic aromatic group or a heterocyclic group, which may be the same as or different from R1 and R2, or a bifunctional group having a monocyclic aromatic group, polycyclic aromatic group or heterocyclic group bonded to each side of a group selected from the group consisting of a single bond, O, CH2, S, SO2, CH2OCH2, OCH2, OCH2CH2OCH2, OCH2OCH2CH2 and CH2OCH2CH2, or a salt thereof, and a composition for controlling the intracellular calcium concentration, which comprises the compound or salt thereof as an active ingredient.

    摘要翻译: 由通式(I)表示的双硼化合物:其中B表示硼原子,Y表示氧或硫原子,R1和R2独立地表示单环芳基,多环芳基或含有至少一个 选自氧,氮和硫原子的杂原子,R 3表示氢原子; - (CH 2)m -NR 4 R 5; -CO-(CH 2)m -NR 4 R 5; -COCH(NH 2)R 6; -CHR7R8; -CH 2 CH(NH 2)-R 9; 被C1-C4烷基取代的喹啉基; 或被吡啶基,哌啶子基或吡咯烷基取代的C1-C4烷基,X表示可以与R1和R2相同或不同的单环芳基,多环芳基或杂环基,或具有 或选自由单键,O,CH2,S,SO2,CH2OCH2,OCH2,OCH2CH2OCH2,OCH2OCH2CH2和CH2OCH2CH2组成的组中的一个基团键合的单环芳基,多环芳基或杂环基,或其盐, 以及用于控制细胞内钙浓度的组合物,其包含其化合物或其盐作为活性成分。

    RNA-binding protein
    8.
    发明申请
    RNA-binding protein 审中-公开
    RNA结合蛋白

    公开(公告)号:US20060019261A1

    公开(公告)日:2006-01-26

    申请号:US10943015

    申请日:2004-09-17

    摘要: The present invention provides Synaptotagmin-binding and yet RNA-binding proteins and genes encoding the proteins. The invention relates to a recombinant protein selected from the group consisting of the following (a) and (b), as well as a gene encoding the protein: (a) a protein comprising the amino acid sequence as shown in SEQ ID NO: 2 (b) a protein which comprises the amino acid sequence as shown in SEQ ID NO: 2 having deletion, substitution or addition of one or several amino acids and which has RNA binding activity.

    摘要翻译: 本发明提供了Synaptotagmin结合蛋白和编码蛋白质的RNA结合蛋白和基因。 本发明涉及选自以下(a)和(b)的重组蛋白质,以及编码该蛋白质的基因:(a)包含SEQ ID NO:2所示的氨基酸序列的蛋白质 (b)包含SEQ ID NO:2所示的具有缺失,取代或添加一个或几个氨基酸并具有RNA结合活性的氨基酸序列的蛋白质。

    Neurogenesis inducing genes
    9.
    发明授权
    Neurogenesis inducing genes 失效
    神经发生诱导基因

    公开(公告)号:US06921648B2

    公开(公告)日:2005-07-26

    申请号:US10244367

    申请日:2002-09-16

    CPC分类号: C07K14/463

    摘要: The present invention relates to neurogenesis inducing genes. In particular, the present invention provides neurogenesis inducing genes coding for Zic proteins, vectors containing such genes, host cells containing such vectors, proteins produced by such host cells, antibodies raised to such proteins, and therapeutic agents or agents for gene therapy for nervous diseases.

    摘要翻译: 本发明涉及神经发生诱导基因。 特别地,本发明提供了编码Zic蛋白质的神经发生诱导基因,含有这些基因的载体,含有该载体的宿主细胞,由该宿主细胞产生的蛋白质,产生于该蛋白质的抗体,以及用于神经疾病基因治疗的治疗剂或药剂 。